Drug Profile

SAN 300

Alternative Names: Anti-VLA-1 antibody - Salix; Anti-VLA-1 mAb; SAN-300; SLX-G1058

Latest Information Update: 24 Oct 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Biogen Idec
Developer Salix Pharmaceuticals
Class Antirheumatics; Monoclonal antibodies
Mechanism of Action Integrin alpha1beta1 antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase II Rheumatoid arthritis

Most Recent Events

30 Jul 2019 SAN-300 is still in phase II trial for Rheumatoid arthritis (Treatment-experienced) in USA (SC) (Salix Pharmaceuticals pipeline - July 2019)
23 Mar 2017 Valeant completes a phase II trial in Rheumatoid arthritis (Treatment-experienced) in USA (SC) (NCT02047604)
15 Jan 2016 Phase-II development is ongoing in USA

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com